- Home
- SPKL vs GBIO Comparison
SPKL vs GBIO Comparison
Compare SPKL & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPKL
- GBIO
- Stock Information
- Founded
- SPKL 2021
- GBIO 2016
- Country
- SPKL United States
- GBIO United States
- Employees
- SPKL N/A
- GBIO N/A
- Industry
- SPKL
- GBIO Biotechnology: Pharmaceutical Preparations
- Sector
- SPKL
- GBIO Health Care
- Exchange
- SPKL Nasdaq
- GBIO Nasdaq
- Market Cap
- SPKL 174.6M
- GBIO 64.8M
- IPO Year
- SPKL 2023
- GBIO 2020
- Fundamental
- Price
- SPKL $10.66
- GBIO $0.88
- Analyst Decision
- SPKL
- GBIO Strong Buy
- Analyst Count
- SPKL 0
- GBIO 2
- Target Price
- SPKL N/A
- GBIO $6.50
- AVG Volume (30 Days)
- SPKL 44.7K
- GBIO 581.0K
- Earning Date
- SPKL 01-01-0001
- GBIO 03-05-2025
- Dividend Yield
- SPKL N/A
- GBIO N/A
- EPS Growth
- SPKL N/A
- GBIO N/A
- EPS
- SPKL 0.19
- GBIO N/A
- Revenue
- SPKL N/A
- GBIO $18,582,000.00
- Revenue This Year
- SPKL N/A
- GBIO $212.74
- Revenue Next Year
- SPKL N/A
- GBIO N/A
- P/E Ratio
- SPKL $57.45
- GBIO N/A
- Revenue Growth
- SPKL N/A
- GBIO 514.08
- 52 Week Low
- SPKL $10.18
- GBIO $0.75
- 52 Week High
- SPKL $11.95
- GBIO $4.65
- Technical
- Relative Strength Index (RSI)
- SPKL 61.06
- GBIO 28.66
- Support Level
- SPKL $10.63
- GBIO $0.85
- Resistance Level
- SPKL $10.66
- GBIO $1.01
- Average True Range (ATR)
- SPKL 0.02
- GBIO 0.12
- MACD
- SPKL 0.00
- GBIO 0.00
- Stochastic Oscillator
- SPKL 75.00
- GBIO 7.50
About SPKL Spark I Acquisition Corp.
Spark I Acquisition Corp is a Blank check company.
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.